A developer of ADCs today, CEO Robin Carr describes how the company’s N-myristoyltransferase (NMT) payload approach sets them apart.

Alex Thompson gives his general take on I&I and comments on argenx, Immunovant, Ascendis, Celldex, Third Harmonic, Apogee, Spyre,...

Denise Scots-Knight describes what Mereo and its partner Ultragenyx have seen in setrusumab data over time, and her description of the...

Thierry Bernard describes the scientific advances underlying QIAGEN's four business pillars: sample technologies, diagnostic solutions,...

John Quisel describes how bitopertin aims to reduce PPIX, a photosensitiser that makes it painful for patients when exposed to light....

Joanna Stanicka describes how Axonis is developing a small molecule that is KCC2-potentiating, with the idea to restore the role that...

Ilan Zipkin of Breakout Ventures says his firm looks at how cell therapies can be augmented with other technologies to help them succeed.

Founding Managing Director Adrien Cohen describes how this $30M fund has been structured, what typical investments will look like, and...

James Guest describes a recent clinical trial success using electrical stimulation of the cervical spinal cord, and also discusses best...

Angela Ruban describes how NeuroHagana is developing a treatment to lower blood glutamate levels that she believes would ideally be...

Brian Skorney gives his take on biotech and discusses Sarepta, Lexeo, Gilead, Mirum, Amgen, Vertex, Neurocrine, and Applied Therapeutics.

Paul Bradshaw explains how Inteligex's "ReStaRT Cells" are designed with a regional identity, and the rationale for engineering them to...

Mike Kelly explains the scientific rational for this peptide-based treatment, highlights its preclinical and phase 1 profile, and...

Laura Sepp-Lorenzino shares details of this news and offers her opinion of the significance of it, and provides an overview of Intellia's...

Brian Culley describes the need for an spinal cord injury focused investor conference and how the SCI Investor Symposium has grown over...

Paul Bolno highlights biomarker and safety data in Huntington's, the potential regulatory path ahead, and what to watch throughout the rest

Chris Hollowood gives his take on biotech, the UK, portfolio companies iOnctura, Yellowstone Biosciences, and Spur Therapeutics...

She describes how patients might benefit from UroGen's gel based technology that keeps chemotherapy locally in the bladder vs having...

David Domzalski discusses how Vyne is using this target that is traditionally thought of in oncology.